{"schema_version":"secwatch.filing_event.v1","accession":"0001279569-23-000639","form_type":"8-K","ticker":"CWBHF","cik":"0001750155","company_name":"Charlotte's Web Holdings, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.374603+00:00","generated_at":"2026-06-15T02:39:58.194434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Charlotte's Web Q1 revenue falls 12.1% to $17M; net loss narrows to $2.9M","bullets":["Revenue $17.0M, down 12.1% YoY from $19.4M; driven by lower oil tincture volume and mix shift to gummies.","Net loss $2.9M vs $8.6M YoY; included $5.4M fair value gain on debt; adjusted EBITDA loss $3.3M.","Operating expenses reduced 14% YoY to $17.5M; operating loss improved to $7.6M from $8.6M.","Cash $60.8M; launched ReCreate broad-spectrum CBD tincture (NSF Certified for Sport) with MLB partnership.","Formed DeFloria LLC with AJNA BioSciences and BAT for botanical IND pathway targeting neurological condition."],"urls":{"canonical":"https://secwatch.observer/filing/0001279569-23-000639","json":"https://secwatch.observer/filing/0001279569-23-000639.json","markdown":"https://secwatch.observer/filing/0001279569-23-000639.md","text":"https://secwatch.observer/filing/0001279569-23-000639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750155/000127956923000639/0001279569-23-000639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750155/000127956923000639/charlottes8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:39:58.194434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7c6c1d5beb0ccc62d818bfaa226ff9f508492a2","claim":"Charlotte's Web Holdings, Inc. reported the first quarter ended March 31, 2023 results: revenue $17.0 million, net income Net loss $ (2.9 ), EPS $(0.02) per share.","evidence_excerpt":"5.4 0.1 Net loss $ (2.9 ) $ (8.6 ) Net loss per common share, basic and diluted $ (0.02 ) $ (0.06 ) Consolidated net revenue for the first quarter ended March 31, 2023, was $17.0 million, a decrease of 12.1% from $19.4 million in the first quarter of 2022. The decrease was primarily due to lower oil tincture sales volume and related product mix for the periods.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750155/000127956923000639/0001279569-23-000639-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$17.0 million"},{"label":"Net income","value":"Net loss $ (2.9 )"},{"label":"EPS","value":"$(0.02) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}